A case for passive immunoprophylaxis against tuberculosis

Lancet Infectious Diseases

Volumn 6, Issue 12, 2006, Pages 813-818

  Reljic, Rajko ^a,b   Ivanyi, Juraj ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; ALPHA CRYSTALLIN; BCG VACCINE; LIPOARABINOMANNAN;

AFRICA; ARTICLE; BCG VACCINATION; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; MYCOBACTERIUM TUBERCULOSIS; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SHORT COURSE THERAPY; SOUTHEAST ASIA; SUPERINFECTION; T LYMPHOCYTE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 33845457506     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(06)70658-2     Document Type: Note

References (60)

1. Nunn P., Williams B., Floyd K., Dye C., Elzinga G., and Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 5 (2005) 819-826
2. Aaron L., Saadoun D., Calatroni I., et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 10 (2004) 388-398
3. McShane H. Co-infection with HIV and TB: double trouble. Int J STD AIDS 16 (2005) 95-100
4. Sonnenberg P., Glynn J., Fielding K., Murray J., Godfrey-Faussett P., and Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 191 (2005) 150-158
5. Corbett E., Watt C., Walker N., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 (2003) 1009-1021
6. Williams B., Granich R., Chauhan L., Dharmshaktu N., and Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc Natl Acad Sci USA 102 (2005) 9619-9624
7. Williams B., and Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301 (2003) 1535-1537
8. Lawn S., Bekker L., and Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 19 (2005) 1113-1124
9. Apers L., Lynen L., Worodria W., and Colebunders R. Review editorial: prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment. Trop Med Int Health 10 (2005) 1209-1214
10. Elliott A., Hayes R., Halwiindi B., et al. The impact of HIV on infectiousness of pulmonary tuberculosis: a community study in Zambia. AIDS 7 (1993) 981-987
11. Barnes P., Yang Z., Pogoda J., et al. Foci of tuberculosis transmission in central Los Angeles. Am J Respir Crit Care Med 159 (1999) 1081-1086
12. Odhiambo J., Borgdorff M., Kiambih F., et al. Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996. Am J Public Health 89 (1999) 1078-1082
13. Orenstein J., Fox C., and Wahl S. Macrophages as a source of HIV during opportunistic infections. Science 276 (1997) 1857-1861
14. Lawn S., Pisell T., Hirsch C., Wu M., Butera S., and Toossi Z. Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 184 (2001) 1127-1133
15. Kitaura H., Ohara N., Kobayashi K., and Yamada T. TNF-alpha-mediated activation of HIV-1 LTR in monocytoid cells by mycobacteria. FEMS Immunol Med Microbiol 31 (2001) 97-103
16. Goletti D., Carrara S., Vincenti D., et al. Inhibition of HIV-1 replication in monocyte-derived macrophages by Mycobacterium tuberculosis. J Infect Dis 189 (2004) 624-633
17. Emori Y., Ikeda T., Ohashi T., et al. Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virol 85 (2004) 2603-2613
18. Dowdy D., Chaisson R., Moulton L., and Dorman S. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS 20 (2006) 751-762
19. Currie C., Williams B., Cheng R., and Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure?. AIDS 17 (2003) 2501-2508
20. Andries K., Verhasselt P., Guillemont J., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 (2005) 223-227
21. Lawn S., Bekker L., and Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5 (2005) 361-373
22. Ha S., Jeon B., Youn J., Kim S., Cho S., and Sung Y. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther 12 (2005) 634-638
23. Korenromp E., Scano F., Williams B., Dye C., and Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 37 (2003) 101-112
24. Doherty T. Real world TB vaccines: clinical trials in TB-endemic regions. Vaccine 23 (2005) 2109-2114
25. McShane H., Pathan A., Sander C., Goonetilleke N., Fletcher H., and Hill A. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 85 (2005) 47-52
26. Nagelkerke N., de Vlas S., Mahendradhata Y., Ottenhoff T., and Borgdorff M. The search for a tuberculosis vaccine: an elusive quest?. Tuberculosis (Edinb) 86 (2006) 41-46
27. Gong J., Stenger S., Zack J., et al. Isolation of mycobacterium-reactive CD1-restricted T cells from patients with human immunodeficiency virus infection. J Clin Invest 101 (1998) 383-389
28. Lauw F., van Der Meer J., de Metz J., Danner S., and van Der Poll T. No beneficial effect of interferon-gamma treatment in 2 human immunodeficiency virus-infected patients with Mycobacterium avium complex infection. Clin Infect Dis 32 (2001) 81-82
29. Johnson J., Ssekasanvu E., Okwera A., et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 168 (2003) 185-191
30. Mwinga A., Nunn A., Ngwira B., et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 360 (2002) 1050-1055
31. Mackaness G. The immunology of antituberculous immunity. Am Rev Respir Dis 97 (1968) 337-344
32. Glatman-Freedman A., and Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 11 (1998) 514-532
33. Costello A., Kumar A., Narayan V., et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis?. Trans R Soc Trop Med Hyg 86 (1992) 686-692
34. Sanchez-Rodriguez C., Estrada-Chavez C., Garcia-Vigil J., et al. An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis. Int J Tuberc Lung Dis 6 (2002) 706-712
35. Vordermeier H., Venkataprasad N., Harris D., and Ivanyi J. Increase of tuberculous infection in the organs of B cell-deficient mice. Clin Exp Immunol 106 (1996) 312-316
36. Rodriguez A., Tjarnlund A., Ivanyi J., et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 23 (2005) 2565-2572
37. Teitelbaum R., Glatman-Freedman A., Chen B., et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA 95 (1998) 15688-15693
38. Pethe K., Alonso S., Biet F., et al. The heparin-binding haemagglutinin of M tuberculosis is required for extrapulmonary dissemination. Nature 412 (2001) 190-194
39. Chambers M., Gavier-Widen D., and Hewinson R. Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiol 41 (2004) 93-100
40. Hamasur B., Haile M., Pawlowski A., Schroder U., Kallenius G., and Svenson S. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol 138 (2004) 30-38
41. Williams A., Reljic R., Naylor I., et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 111 (2004) 328-333
42. Reljic R., Clark S., Williams A., et al. Intranasal interferon gamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection. Clin Exp Immunol 143 (2006) 467-473
43. Guirado E., Amat I., Gil O., et al. Passive serum-therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 8 (2006) 1252-1259
44. Roy E., Stavropoulos E., Brennan J., et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 73 (2005) 6101-6109
45. Jackett P., Bothamley G., Batra H., Mistry A., Young D., and Ivanyi J. Specificity of antibodies to immunodominant mycobacterial antigens in pulmonary tuberculosis. J Clin Microbiol 26 (1988) 2313-2318
46. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 47 (2003) 833-836
47. Yuan Y., Crane D., Simpson R., et al. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci USA 95 (1998) 9578-9583
48. Reljic R., Crawford C., Challacombe S., and Ivanyi J. Mouse IgA inhibits cell growth by stimulating tumor necrosis factor-alpha production and apoptosis of macrophage cell lines. Int Immunol 16 (2004) 607-614
49. Reljic R., Williams A., and Ivanyi J. Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?. Tuberculosis (Edinb) 86 (2006) 179-180
50. de Valliere S., Abate G., Blazevic A., Heuertz R., and Hoft D. Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infect Immun 73 (2005) 6711-6720
51. Moore T., Ekworomadu C., Eko F., et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 188 (2003) 617-624
52. Brady L. Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens. Infect Immun 73 (2005) 671-678
53. Bourgarit A., Carcelain G., Martinez V., et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20 (2006) 1-7
54. Van den Bergh R., Vanham G., Raes G., De Baetselier P., and Colebunders R. Mycobacterium-associated immune reconstitution disease: macrophages running wild?. Lancet Infect Dis 6 (2006) 2-3
55. Lawn S. Mycobacterium-associated immune reconstitution disease: macrophages running wild? Author's reply. Lancet Infect Dis 6 (2006) 4-5
56. Schnappinger D., Ehrt S., Voskuil M., et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 198 (2003) 693-704
57. Casadevall A. Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect Immun 71 (2003) 4225-4228
58. Feldmann M., and Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 435 (2005) 612-619
59. Waldmann H., and Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 360 (2005) 1707-1711
60. Sonnenberg P., Murray J., Glynn J., Shearer S., Kambashi B., and Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358 (2001) 1687-1693